Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 11Thoracic 10Genitourinary 8Head & Neck 7Other hematologic neoplasm 6Lymphoid 5Gynecologic 5Gastrointestinal 5Breast 4Dermatologic 3CNS 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other neoplasm 1Other 1Myeloid 1

Conditions

Endometrial Clear Cell Adenocarcinoma 1

Interventions

Doxorubicin 25Cyclophosphamide 24pembrolizumab 20Specimen Handling 19Temozolomide 16Surgical Procedures, Operative 14Magnetic Resonance Spectroscopy 14Gemcitabine 13Blood Specimen Collection 13Biopsy 13Radiotherapy 12fludarabine 11atezolizumab 11Vincristine 11Ifosfamide 11X-Rays 8Trabectedin 8Nivolumab 8Irinotecan 8Imatinib Mesylate 8Drug Therapy 8cabozantinib 7Surveys and Questionnaires 7Radiation 6selinexor 5liposomal doxorubicin 5Sunitinib 5Standard of Care 5Radiation Dose Hypofractionation 5Dactinomycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Practice Guidelines as Topic × Sarcoma × Clear all
NCT03422198 2025-12-12

SAVE

University of Utah

Phase 3 Recruiting
188 enrolled 15 charts
GynecologicSarcoma

Endometrial Clear Cell Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡